January 2017—EntroGen launched its Leukemia Translocation Panel, a multiplexed, one-step RT-PCR assay that detects 10 variants in six common leukemia-associated translocations simultaneously from total RNA isolated from blood or bone marrow. The assay is compatible with several leading multichannel real-time PCR instruments capable of detecting four commonly used fluorescent probes and produces results in 90 minutes.
EntroGen also offers separate, one-step RT-PCR kits for detecting BCR-ABL fusion transcripts p190 and p210 that may be run together with the Leukemia Translocation Panel for a comprehensive test for fusion genes implicated in chronic myeloid leukemia, acute lymphoblastic leukemia, acute promyelocytic leukemia, and acute myeloid leukemia. Following initial diagnosis, EntroGen offers separate quantitative kits specific to each individual fusion gene transcript for monitoring residual disease.
All kits come with data analysis software to automate reporting. BCR-ABL p210 also includes World Health Organization standards that enable reporting on the International Scale.
EntroGen, 818-716-1070